DE69027865D1 - ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN - Google Patents

ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN

Info

Publication number
DE69027865D1
DE69027865D1 DE69027865T DE69027865T DE69027865D1 DE 69027865 D1 DE69027865 D1 DE 69027865D1 DE 69027865 T DE69027865 T DE 69027865T DE 69027865 T DE69027865 T DE 69027865T DE 69027865 D1 DE69027865 D1 DE 69027865D1
Authority
DE
Germany
Prior art keywords
ischemic
treatment
compositions containing
neuronal damage
conotoxin peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69027865T
Other languages
English (en)
Other versions
DE69027865T2 (de
Inventor
George Miljanich
Robert Bitner
Stephen Bowersox
James Fox
Karen Valentino
Donald Yamashiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Corp PLC
Original Assignee
Neurex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurex Corp filed Critical Neurex Corp
Application granted granted Critical
Publication of DE69027865D1 publication Critical patent/DE69027865D1/de
Publication of DE69027865T2 publication Critical patent/DE69027865T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
DE69027865T 1989-11-22 1990-11-21 ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN Expired - Fee Related DE69027865T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/440,094 US5051403A (en) 1989-11-22 1989-11-22 Method of treating ischemia-related neuronal damage
PCT/US1990/006853 WO1991007980A1 (en) 1989-11-22 1990-11-21 Compositions for treating ischemia-related neuronal damage

Publications (2)

Publication Number Publication Date
DE69027865D1 true DE69027865D1 (de) 1996-08-22
DE69027865T2 DE69027865T2 (de) 1997-01-02

Family

ID=23747411

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69027865T Expired - Fee Related DE69027865T2 (de) 1989-11-22 1990-11-21 ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN

Country Status (12)

Country Link
US (1) US5051403A (de)
EP (1) EP0593450B1 (de)
JP (1) JP3809184B2 (de)
AT (1) ATE140388T1 (de)
AU (1) AU648052B2 (de)
CA (1) CA2045473C (de)
DE (1) DE69027865T2 (de)
DK (1) DK0593450T3 (de)
ES (1) ES2091906T3 (de)
GR (1) GR3021087T3 (de)
HK (1) HK1006810A1 (de)
WO (1) WO1991007980A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876958A (en) * 1988-04-04 1999-03-02 Sibia Neurosciences, Inc. Assays of cells expressing human calcium channels containing α1 β subunits
US20040018510A1 (en) 1990-11-08 2004-01-29 Merck & Co., Inc. Human calcium channel compositions and methods
US6096514A (en) * 1988-04-04 2000-08-01 Sibia Neurosciences, Inc. Human calcium channel compositions and methods
US5386025A (en) * 1990-02-20 1995-01-31 The Salk Institute Biotechnology/Industrial Associates Calcium channel compositions and methods
US5846757A (en) * 1988-04-04 1998-12-08 Sibia Neurosciences, Inc. Human calcium channel α1, α2, and β subunits and assays using them
US5874236A (en) * 1988-04-04 1999-02-23 Sibia Neurosciences. Inc. DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits
US6387696B1 (en) 1988-04-04 2002-05-14 Merck & Co., Inc. Human calcium channel compositions and methods
US6653097B1 (en) 1991-08-15 2003-11-25 Merck & Co., Inc. Human calcium channel compositions and methods
US5851824A (en) * 1988-04-04 1998-12-22 Sibia Neurosciences, Inc. Human calcium channel α-1C/α-1D, α-2, β-1, and γsubunits and cells expressing the DNA
US5407820A (en) * 1988-04-04 1995-04-18 The Salk Institute Biotechnology/Industrial Associates, Inc. Calcium channel α-2 subunit DNAs and cells expressing them
DE68926713T2 (de) 1988-04-04 1996-11-14 Salk Inst Biotech Ind Calciumkanal-zusammensetzungen und verfahren
US5559095A (en) * 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
US5264371A (en) * 1989-11-22 1993-11-23 Neurex Corporation Screening method for neuroprotective compounds
WO1993010145A1 (en) * 1991-11-12 1993-05-27 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
DE69225499T2 (de) * 1991-12-30 1999-02-04 Neurex Corp Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
EP0556160A3 (de) * 1992-02-11 1993-10-27 Sandoz Ag Insektizide Toxine von Plectreurys tristis
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5514774A (en) * 1993-06-29 1996-05-07 University Of Utah Research Foundation Conotoxin peptides
US5591821A (en) * 1993-07-16 1997-01-07 The University Of Utah Omega-conotoxin peptides
US6090623A (en) * 1993-08-11 2000-07-18 Merck & Co., Inc. Recombinant human calcium channel β4 subunits
US5739276A (en) * 1994-10-07 1998-04-14 University Of Utah Research Foundation Conotoxin peptides
US5670622A (en) * 1996-02-15 1997-09-23 University Of Utah Research Foundation Conotoxin peptide PIIIA
US6054429A (en) * 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
CA2224795C (en) * 1995-06-27 2001-04-03 Neurex Corporation Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
US5965534A (en) * 1995-11-22 1999-10-12 Alcon Laboratories, Inc. Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
US5672682A (en) * 1996-03-18 1997-09-30 University Of Utah Research Foundation Conotoxin peptide PVIIA
US6528630B1 (en) 1997-12-03 2003-03-04 Merck & Co., Inc. Calcium channel compositions and methods
US6379882B1 (en) 1998-09-14 2002-04-30 Elan Pharmaceuticals, Inc. Method for selecting compounds for treating ischemia-related cellular damage
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
AU6415999A (en) * 1998-10-06 2000-04-26 Cognetix, Inc. Kappa-a conopeptides and uses therefor
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
US6268473B1 (en) 1999-01-22 2001-07-31 University Of Utah Research Foundation α-conotoxin peptides
US6855805B2 (en) 1999-01-22 2005-02-15 University Of Utah Research Foundation α-conotoxin peptides
JP2003520199A (ja) * 1999-08-10 2003-07-02 ユーエイビー リサーチ ファンデーション 非ステロイド性抗炎症薬及び天然産コノトキシンを使用する外傷性脳及び脊髄損傷、並びに他の神経原性症状の治療方法
EP1246635A4 (de) 1999-12-30 2004-09-01 Univ Utah Res Found Conotoxin-peptide der o-superfamilie
PT1572725E (pt) 2002-12-02 2012-05-28 Xenome Ltd Péptidos de qui-conotoxina possuindo um ácido piroglutâmico n-terminal
EP2412719A1 (de) 2002-12-02 2012-02-01 Xenome Ltd Chi-Conotoxin-Peptide
US20060019892A1 (en) * 2003-03-05 2006-01-26 Florida Atlantic University Conopeptides and methods of use
US20090062211A1 (en) * 2003-03-05 2009-03-05 Florida Atlantic University Conopeptides and methods of use
US7268109B2 (en) 2003-10-02 2007-09-11 Elan Pharmaceuticals, Inc. Method for reducing pain
CN101018546B (zh) * 2004-09-10 2013-06-12 纽朗制药有限公司 作为钠和/或钙通道选择性调节剂的(卤代苄氧基)苄氨基-丙酰胺类
CN1304422C (zh) * 2005-09-15 2007-03-14 浙江大学 非酰胺化ω－芋螺毒素M ⅦA 及其制备方法和应用
SI1963280T1 (sl) 2005-12-22 2016-02-29 Newron Pharmaceuticals S.P.A. 2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov
US8519000B2 (en) 2007-06-15 2013-08-27 Newron Pharmaceuticals S.P.A. Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
WO2011032233A1 (en) 2009-09-21 2011-03-24 The University Of Queensland Novel omega conotoxin peptides
PL2723710T3 (pl) 2011-06-27 2017-02-28 Newron Pharmaceuticals S.P.A. Fluorowane pochodne aryloalkiloaminokarboksyamidowe
CA2986704C (en) 2015-05-22 2022-03-01 Clemson University Research Foundation Conotoxin peptides for use in biofouling deterrence

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US4950739A (en) * 1988-02-10 1990-08-21 New York University Membrane calcium channels and factors and methods for blocking, isolating and purifying calcium channels

Also Published As

Publication number Publication date
DE69027865T2 (de) 1997-01-02
EP0593450B1 (de) 1996-07-17
CA2045473C (en) 2002-09-17
DK0593450T3 (da) 1996-11-25
EP0593450A1 (de) 1994-04-27
ATE140388T1 (de) 1996-08-15
CA2045473A1 (en) 1991-05-23
GR3021087T3 (en) 1996-12-31
ES2091906T3 (es) 1996-11-16
US5051403A (en) 1991-09-24
JPH05501715A (ja) 1993-04-02
HK1006810A1 (en) 1999-03-19
AU6964091A (en) 1991-06-26
AU648052B2 (en) 1994-04-14
JP3809184B2 (ja) 2006-08-16
WO1991007980A1 (en) 1991-06-13

Similar Documents

Publication Publication Date Title
DE69027865T2 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
BG101118A (en) Therapeutical compounds
DE3482754D1 (de) Medikament und medikamentoese zusammensetzung zur behandlung und/oder verhinderung von hautkrankheiten, verursacht durch eine entzuendung.
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
FI940375A (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
DK0489877T3 (da) Antiatherosklerotiske og antithrombotiske 2-amino-6-phenyl-4H-pyran-4-oner
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
DE2961609D1 (en) Sila-substituted 1,4-dihydropyridine derivatives, processes for their preparation, pharmaceutical compositions and process for their preparation
ES2044170T3 (es) Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.
ES2089286T3 (es) Nuevas 2-amino-5-ciano-1,4-dihidropiridinas, procedimiento para su preparacion y su uso en medicamentos.
ATE27157T1 (de) Cycloalkylderivate von benzisoselenazolonen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
IE870577L (en) Topical amide preparation
DE3687233T2 (de) Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten.
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE30238T1 (de) N-acylderivate von peptiden, ihre herstellung und verwendung bei der bekaempfung von krankheiten und mittel dafuer.
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
MX9203208A (es) Composicion farmaceutica y metodo para el tratamiento de trastornos digestivos.
ATA901889A (de) Verfahren zur herstellung von wasserlöslichem primycin und seinen komponenten sowie von diese enthaltenden pharmazeutischen präparaten
DE69104058T2 (de) N-[(2-thenoylmerkapto-3-methyl)-butanoyl]-homocysteinthiolacton, verfahren zu seiner herstellung und diese enthaltende pharmaceutische zusammensetzungen.
ATE96039T1 (de) Arzneimittel und ihre verwendung zur behandlung von parasitosen.
ATA216783A (de) Verfahren zur herstellung von stabilen pharmazeutischen praeparaten mit antiseptischer underhoehter entzuendungshemmender wirkung zur lokalen anwendung
NO923078D0 (no) Skumbar sammensetning for farmasoeytisk anvendelse, anvendelse derav og fremgangsmaate for behandling

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee